Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma

(2017) Kuisheng Liu et al.   Cell Death & Disease

Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer

(2017) Yansong Lin et al.   Oncotarget

Thyroid Carcinoma, Version 2.2014

(2017) R. Michael Tuttle et al.   Journal of the National Comprehensive Cancer Network

Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib

(2016) Weibin Wang et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

(2016) Jin Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Evolving molecularly targeted therapies for advanced-stage thyroid cancers

(2016) Keith C. Bible et al.   Nature Reviews Clinical Oncology

miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma

(2016) Qian Fan et al.   Protein & Cell

The switch from ER stress-induced apoptosis to autophagy via ROS-mediated JNK/p62 signals: A survival mechanism in methotrexate-resistant choriocarcinoma cells

(2015) Yun Shen et al.   EXPERIMENTAL CELL RESEARCH

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer

(2014) Xichun Hu et al.   BMC CANCER

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer

(2014) Xichun Hu et al.   INTERNATIONAL JOURNAL OF CANCER

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

(2014) Marcia S Brose et al.   LANCET

Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets

(2014) Christine Spitzweg et al.   Lancet Diabetes & Endocrinology

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

(2013) Jin Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer

(2013) Yuan-yuan Li et al.   LUNG CANCER

MG-2477, a new tubulin inhibitor, induces autophagy through inhibition of the Akt/mTOR pathway and delayed apoptosis in A549 cells

(2011) Giampietro Viola et al.   BIOCHEMICAL PHARMACOLOGY

Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells

(2011) Nanae Harashima et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches

(2011) Pamela Jo Harris et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors

(2011) Bruno Calabretta et al.   LEUKEMIA & LYMPHOMA

Autophagy and Metabolism

(2010) J. D. Rabinowitz et al.   SCIENCE

Dedifferentiated thyroid cancer: A therapeutic challenge

(2008) Alessandro Antonelli et al.   BIOMEDICINE & PHARMACOTHERAPY